Yhdysvallat - englanti - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate is indicated for the prevention of: flecainide acetate is also indicated for the prevention of: use of flecainide acetate for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate should not be used in patients with recent myocardial infarction. (see boxed warnings.) use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings.) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or t

Yhdysvallat - englanti - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide is indicated for the prevention of: - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide is also indicated for the prevention of: - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life threatening. use of flecainide for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in th

Yhdysvallat - englanti - NLM (National Library of Medicine)

physicians total care, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of: •paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp,

Yhdysvallat - englanti - NLM (National Library of Medicine)

avkare, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician, are lifethreatening. use of flecainide for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion

Malta - englanti - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - flecainide acetate - tablet - flecainide acetate 50 mg - cardiac therapy

Malta - englanti - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - flecainide acetate - tablet - flecainide acetate 100 mg - cardiac therapy

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - flecainide acetate 100mg;   - tablet - 100 mg - active: flecainide acetate 100mg   excipient: croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water - in patients without structural heart disease and without myocardial infarction, flecainide bnm tablets are indicated for the prevention of: supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic. use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - flecainide acetate 50mg;   - tablet - 50 mg - active: flecainide acetate 50mg   excipient: croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch - in patients without structural heart disease and without myocardial infarction, flecainide bnm tablets are indicated for the prevention of: supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic. use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 100 mg - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

Yhdysvallat - englanti - NLM (National Library of Medicine)

carilion materials management - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 100 mg - in patients without structural heart disease, flecainide acetate is indicated for the prevention of: flecainide acetate is also indicated for the prevention of: use of flecainide acetate for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate should not be used in patients with recent myocardial infarction. (see boxed warnings.) use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings.) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival